Burden and risk factors of dyslipidemia-results from a STEPS survey in Punjab India

Tripathy, Jaya Prasad; Thakur, JS; Jeet, Gursimer; Chawla, Sohan; Jain, Sanjay; Prasad, Rajendra

doi:10.1016/j.dsx.2016.08.015

Cited by 30 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tabrizi et al reported similar results (44). Despite comparable ndings regarding the association between hypertension and hypertriglyceridemia in a study in India, dyslipidemia and other lipid abnormalities were also signi cantly correlated in this study (38).…”

Section: Prevalence Of Dyslipidemia and Individual Lipid Abnormalitiesupporting

confidence: 49%

“…Conversely, Cui et al demonstrated that the prevalence of hypercholesterolemia was higher in rural areas compared to urban areas for women (34). Similarly Tripathy et al demonstrated that living in rural areas increased the risk of dyslipidemia and high TC (38). The reason for these inconsistencies may be the consumption of fat-rich foods such as high-fat dairy by individuals living in rural areas in the two studies.…”

Section: Prevalence Of Dyslipidemia and Individual Lipid Abnormalitiementioning

confidence: 96%

See 1 more Smart Citation

Dyslipidemia and Its Associated Factors in Women of the Bandare-Kong Cohort Study

Nikparvar

Khaladeh

Yousefi

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Dyslipidemia, a major risk factor for cardiovascular diseases, has become a global issue. Due to geographic and demographic variations in the prevalence of dyslipidemia, this study aimed to evaluate dyslipidemia and its associated factors in women of the Bandare-Kong Cohort Study (BKNCD).Methods: This study was conducted on women from the population-based BKNCD, as part of the Prospective Epidemiological Research Studies in IrAN (PERSIAN). Sociodemographic data, medical history, and anthropometric indices were collected. Diastolic blood pressure, systolic blood pressure, fasting plasma glucose, serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured. Daily calorie intake and weekly metabolic equivalent of tasks were also recorded. Dyslipidemia was defined as any lipid abnormality based on the Adult Treatment Panel III criteria. Results: From the 2223 women in this study (mean age: 48.28±9.26 years), dyslipidemia was observed in 1884 (84.8%). High TC was the most common lipid abnormality (53.9%) followed by low HDL (50.8%). Dyslipidemia was most prevalent among women aged 65-70 years, the widowed, illiterate, unemployed, and overweight, with very low socioeconomic status, diabetes, and high waist circumference, hypertension, those using hookah and living in urban areas. Logistic regression revealed that only women with high WHR were at increased risk of dyslipidemia (OR=2.48, 95% CI:1.75-3.53, P<0.001). Having a high school diploma (OR=0.57, 95% CI:0.37-0.89, P=0.015) and living in rural areas (OR=0.68 95% CI:0.49-0.96, P=0.028) were protective.Conclusions: Dyslipidemia was highly prevalent in women of BKNCD. High WHR appears to be the only significant risk factor for dyslipidemia.

show abstract

Section: Prevalence Of Dyslipidemia and Individual Lipid Abnormalitiesupporting

confidence: 49%

Section: Prevalence Of Dyslipidemia and Individual Lipid Abnormalitiementioning

confidence: 96%

Dyslipidemia and Its Associated Factors in Women of the Bandare-Kong Cohort Study

Nikparvar

Khaladeh

Yousefi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Among them, only 1/3 rd had control of glycemia. 2 American Diabetes Association (ADA) guidelines recommend various treatments for T2D including oral antidiabetic drugs (OADs) and insulin in addition to diet and lifestyle therapy. Recently available dipeptidyl peptidase 4 inhibitors (DPP4i) are recommended as second line treatment after metformin.…”

Section: Introductionmentioning

confidence: 99%

Teneligliptin add on to monotherapy treatment in patients with type 2 diabetes

Chatterjee¹

2018

Int J Res Med Sci

View full text Add to dashboard Cite

Background: In patient with type 2 diabetes (T2D) inadequately controlled on monotherapy, teneligliptin is efficacious and safe as add-on to treatment with oral antidiabetic drugs (OADs) or insulin. Data on efficacy of teneligliptin in Indian patients is relatively sparse. Aim of the study was to assess the efficacy of teneligliptin used as add-on treatment in patients inadequately controlled on monotherapy with OADs or insulin.Methods: We retrospectively evaluated the electronic database at our endocrinology clinic from East India. Patients who were treated with teneligliptin (20 mg/day) as add-on to monotherapy with OADs or insulin were identified, and data analysed. Primary assessment parameters were change in glycosylated haemoglobin (HbA1c %), fasting plasma glucose (FPG, mg/dL) and post-prandial plasma glucose (PPG, mg/dL) over 12-week from the addition of teneligliptin. Paired t test and McNemar test applied to derive statistical significance of paired continuous and categorical variables respectively.Results: In 88 patients, teneligliptin was used as add-on treatment in 77.3% and 22.7% patients receiving OAD and insulin as monotherapy respectively. Mean age of population was 48.3±15.1 years and 67% were males. From baseline to 12-weeks, there was significant change in HbA1c (9.6±2.1 to 8.4±1.2%, P<0.001), FPG (181.4±54.5 to 140.9±27.1 mg/dL, P<0.001) and PPG (273.7±75.6 to 201.1±47.7 mg/dL, P<0.001). Reduction in these glycemic parameters was significant in patients with teneligliptin as add-on to either OADs or insulin. Overall, 12.5% patients reached the target HbA1c of <7% after 12-week treatment (P=0.004).Conclusions: In patients who are uncontrolled on monotherapy with either OADs or insulin, addition of teneligliptin resulted in significant reduction of HbA1c, FPG and PPG after 12-week treatment. This establishes usefulness of teneligliptin in Indian patients with T2D. A larger, randomized, comparative study with other gliptins is warranted.

show abstract

“…Uric acid is a final enzyme product in the degradation of nucleotide purine. It can trap oxygen free radicals and protect erythrocyte membrane lipid oxidation [3,4]. Some studies have shown that hyperuricemia is a risk factor for CVD in the general population [7][8][9][10][11][12][13] and studies on laboratory animals have also shown that a high concentration of uric acid plays a causal role in SM [14,15].…”

Section: Discussionmentioning

confidence: 99%

“…Hyperuricemia is a common Type 2 diabetes at very high cardiovascular risk and increasing the morbidity and mortality rates. Thus, the growing burden of long-term diabetes indicates that prevention is urgently needed, underscoring the need for early identification of modifiable risk factors [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Risk Factors Associated With Hyperuricemia in Patients with Diabetes Type 2: About 190 Cases

Fennoun

et al. 2020

Diab Res Open Access

View full text Add to dashboard Cite

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

show abstract

Burden and risk factors of dyslipidemia-results from a STEPS survey in Punjab India

Cited by 30 publications

References 12 publications

Dyslipidemia and Its Associated Factors in Women of the Bandare-Kong Cohort Study

Dyslipidemia and Its Associated Factors in Women of the Bandare-Kong Cohort Study

Teneligliptin add on to monotherapy treatment in patients with type 2 diabetes

Risk Factors Associated With Hyperuricemia in Patients with Diabetes Type 2: About 190 Cases

Contact Info

Product

Resources

About